In COPD, muscular atrophy is a significant risk factor for death and may prolong patients’ hospital length of stay.

In acute infective exacerbation of chronic bronchitis or chronic obstructive pulmonary disease (COPD), adding erdosteine to standard treatment significantly modified the outcome by improving the ...

Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This ...

The effect of erdosteine on mucus rheological properties was evaluated in patients with exacerbation of COPD. [24] Patients ... at day 3 and at the end of the treatment compared with the placebo ...

The global acute respiratory distress syndrome (ARDS) treatment market was valued at approximately USD $$ billion in 2022 and is expected to grow at a robust CAGR of more than $% during the forecast ...

But a spectrum of non-pharmacological ways of treating COPD are also available and important ... and exercise capacity after 12 months. The treatment groups were “not well-matched,” researchers found, ...

Pope Francis has been hospitalized for several days due to bilateral pneumonia. So, what are the symptoms, and who is more ...

After Pope Francis was hospitalized on February 14 to receive treatment for bronchitis, the Vatican has now announced that ...

Resident physicians at the Detroit Medical Center are organizing to fight for better wages, working conditions and lower ...

Thus, deciphering the relationships between host and resident or colonizing microbes is essential for proper diagnosis, prognosis, management, and treatment of respiratory ... and chronic obstructive ...

Does gabapentinoid use increase the risk of severe exacerbation in patients with chronic obstructive pulmonary disease (COPD) ...